RGNX

REGENXBIO Inc. - Common Stock (RGNX)

About REGENXBIO Inc. - Common Stock (RGNX)

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Details

Daily high

$8.83

Daily low

$8.16

Price at open

$8.67

52 Week High

$15.36

52 Week Low

$5.04

Market cap

424.8M

Dividend yield

0.00%

Volume

3.5M

Avg. volume

1.3M

P/E ratio

-2.69

REGENXBIO Inc. - Common Stock News